Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 5/20 | 0.61 |
| ▸ | ADH1A | P07327 | 5/20 | 0.61 |
| ▸ | ADH1C | P00326 | 4/20 | 0.61 |
| ▸ | ADH7 | P40394 | 4/20 | 0.61 |
| ▸ | ADH4 | P08319 | 2/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5646910 | 1.00 | ADH1B (0.61) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL5649841 | 0.98 | ADH1B (0.58) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL3020274 | 0.93 | — | — | |
| SCHEMBL1899269 | 0.88 | — | — | |
| SCHEMBL304406 | 0.87 | ADH1B (0.57) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL303075 | 0.87 | ADH1B (0.57) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL8861073 | 0.85 | SIGMAR1 (0.60) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL8952319 | 0.85 | SIGMAR1 (0.60) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL22104300 | 0.84 | ADH1B (0.54) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL3024930 | 0.84 | ADH1B (0.54) | ADH1BADH1AADH1CADH7ADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661436-B1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2016-04-13 | — | — | EP | claimed |
| US-9233964-B2 | Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof | LEO PHARMA A/S (DK) | 2016-01-12 | — | — | US | claimed |
| US-20130345194-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2013-12-26 | — | — | US | claimed |
| EP-2661436-A1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2013-11-13 | — | — | EP | claimed |
| WO-2012093169-A1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | WO | claimed |
| US-4716162-A | BRAIN FUNCTION | SANKYO COMPANY, LIMITED (JP) | 1987-12-29 | — | — | US | claimed |
| CN-111491923-B | N- (2-cyclohexylethyl) carboxamide derivatives, preparation and pharmaceutical use thereof | 上海海雁医药科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-111491923-B | N- (2-cyclohexylethyl) carboxamide derivatives, preparation and pharmaceutical use thereof | 上海海雁医药科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-111491923-B | N- (2-cyclohexylethyl) carboxamide derivatives, preparation and pharmaceutical use thereof | 上海海雁医药科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| WO-2023007009-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-02-02 | — | — | WO | disclosed |
| CN-111491923-A | N- (2-cyclohexylethyl) formamide derivatives, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2020-08-04 | — | — | CN | disclosed |
| CN-111491923-A | N- (2-cyclohexylethyl) formamide derivatives, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2020-08-04 | — | — | CN | disclosed |
| CN-111491923-A | N- (2-cyclohexylethyl) formamide derivatives, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2020-08-04 | — | — | CN | disclosed |
| WO-2000063208-A1 | SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000037464-A2 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2000-06-29 | — | — | WO | disclosed |
| EP-0981958-A1 | INSECTICIDAL/ACARICIDAL AGENTS | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2000-03-01 | — | — | EP | disclosed |
| US-5506239-A | Carbostyril derivative and platelets aggregation inhibitory agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-09 | — | — | US | disclosed |
| EP-0171217-B1 | FUSED-RING HETEROCYCLIC COMPOUNDS A PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | SANKYO COMPANY LIMITED (JP) | 1989-05-03 | — | — | EP | disclosed |
| US-4716162-A | BRAIN FUNCTION | SANKYO COMPANY, LIMITED (JP) | 1987-12-29 | — | — | US | disclosed |
| EP-0171217-A2 | Fused-ring heterocyclic compounds a process for their production and their pharmaceutical use | SANKYO COMPANY LIMITED (JP) | 1986-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345194-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | JAK1, CNKSR1, TSHR | ADH1B 921/4885ADH1A 1164/4885ADH1C 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.